Composition for anti-fatigue or fatigue recovery

Abstract

To provide an anti-fatigue or fatigue-recovery composition containing, as an active ingredient, a highly safe substance that prevents or helps recover from post-exercise fatigue.SOLUTION: Many conventional anti-fatigue or fatigue-recovering compositions mainly use amino acid peptides, and the effect of monosaccharide, which has 0 kcal / g of energy when ingested, on anti-fatigue or fatigue recovery was not known. On the other hand, D-psicose is a monosaccharide with 0 kcal / g energy, yet its safety has been well confirmed through dietary experience and various safety tests. Since it has now become clear that D-psicose helps recover from fatigue after exercise, the above object is achieved by providing a composition containing D-psicose.SELECTED DRAWING: Figure 2

Description

Technical Field

[0001] The present invention relates to a composition for anti-fatigue or fatigue recovery.

Background Art

[0002] Fatigue includes mental fatigue and physical fatigue. For example, the Japanese Society of Fatigue Science defines it as "a state of decline in physical activity ability accompanied by a unique discomfort and a desire for rest caused by excessive physical and mental activities or diseases."

[0003] In recent years, various components for anti-fatigue or fatigue recovery have been proposed to prevent or improve such fatigue. For example, anti-fatigue or fatigue recovery compositions using imidazole dipeptides (Patent Documents 1 and 2), anti-fatigue or fatigue recovery compositions using whey protein hydrolysates (Patent Document 3), fatigue recovery compositions containing glutathione (Patent Document 4), etc. have been disclosed.

Prior Art Documents

Patent Documents

[0004]

Patent Document 1

Patent Document 2

Patent Document 3

Patent Document 4

Summary of the Invention

Problems to be Solved by the Invention

[0005] An object of the present invention is to provide an anti-fatigue or fatigue recovery composition containing, as an active ingredient, a substance having high safety and capable of preventing or recovering fatigue after exercise.

Means for Solving the Problems

[0006] Conventional anti-fatigue or fatigue recovery compositions have mainly utilized amino acid peptides, and the effect of monosaccharides, especially monosaccharides with an energy content of 0 kcal / g upon ingestion, on anti-fatigue or fatigue recovery has not been known until now. Under these circumstances, the inventors of this invention discovered that D-psicose, a monosaccharide with an energy content of 0 kcal / g, helps to recover from fatigue after exercise, and thus completed the present invention.

[0007] The present invention consists of the following [1] to [2]. [1] A composition for anti-fatigue or fatigue recovery, comprising D-psicose. [2] The composition described in [1] above, wherein 0.3 to 50 g / kg body weight of D-psicose is ingested per day for 7 days or more. [Effects of the Invention]

[0008] The composition of the present invention is highly safe and can be taken continuously on a daily basis. With appropriate intake, it can shorten the time required to recover from fatigue after exercise. [Brief explanation of the drawing]

[0009] [Figure 1] This graph plots the number of times each 9-week-old mouse that underwent forced exercise rotated a cage-based wheel, measured daily, averaged, and divided by the average number of rotations over the 7 days prior to forced exercise, against the number of days elapsed (at this point, neither the treatment group AE nor the control group E had received D-psicose, and the group division is retrospective). [Figure 2] After the completion of the experiment shown in Figure 1, a four-week interval was taken, and each mouse, now 14 weeks old, underwent a second forced exercise session. Subsequently, the number of times each mouse rotated the rotating wheel inside the cage was measured daily and averaged. This average was then divided by the average number of rotations during the seven days prior to the second forced exercise session, and the result was plotted against the number of days elapsed. [Modes for carrying out the invention]

[0010] In this invention, "fatigue recovery" includes the prevention of fatigue, but mainly refers to recovering from or promoting fatigue recovery after exercise. For example, if the normal average exercise amount of an individual is set to 100, it means that the time required for the average exercise amount after a certain amount of exercise to approach 100 is shorter than usual, or that the individual is able to exercise at a level exceeding the average exercise amount of a typical individual within a short time after a certain amount of exercise. More specifically, as described in J Phys Fitness Sports Med, 2(3): 373-379 (2013), if the average number of times a mouse rotates a wheel in its cage per day during the period without active ingredient intake is set to 100, then "fatigue recovery" can be determined when, after administering the active ingredient to a mouse and returning it to its cage after forced exercise on a treadmill, the number of days required for the number of rotations of the wheel per day to approach 100 is less than that of the untreated mouse group, or when the number of rotations of the wheel is significantly higher than that of the untreated mouse group.

[0011] The "D-psicose" used in this invention can be a commercially available product. As a product containing a high amount of D-psicose, for example, "Astraea" (manufactured by Matsutani Chemical Industry Co., Ltd.) can be used. As a mixed product, for example, "Rare Sugar Sweet" (manufactured by Matsutani Chemical Industry Co., Ltd.), which contains about 7% D-psicose, can be used. However, in the case of a mixed syrup like the latter, a powdering process is required to make it into a powder, and since the amount of the active ingredient D-psicose is very small, and the majority consists of unnecessary D-glucose and D-fructose, it is preferable to use a D-psicose-containing powder or crystalline product containing at least 15% by mass, preferably 20% by mass, and more preferably 30% by mass or more of D-psicose. Furthermore, D-psicose can be measured using high-performance liquid chromatography, a commonly known method for analyzing sugars (for example, see Takamine et al., "Method for producing rare sugar-containing syrup using alkali isomerization and its inhibitory effect on α-glucosidase," Applied Carbohydrate Science (2015), Vol. 5, No. 1, pp. 44-49).

[0012] The fatigue-recovering effect described in this invention is obtained when a composition containing D-psicose as an active ingredient is administered. Oral administration is the simplest method of administration, but parenteral administration such as intravenous, intraperitoneal, and subcutaneous administration is also possible. Examples of the composition to be administered include tablets, granules, capsules, and syrups for oral intake, and injections, drips, topical applications, and suppositories for parenteral intake. In order to efficiently administer the effective amount described later, it is sufficient for the composition to contain approximately 0.1-50% or 3-30% of D-psicose.

[0013] The dosage of D-psicose, the active ingredient of the present invention, should be an amount that exerts the effect of the present invention. While it may vary slightly depending on the administration method, the age and weight of the recipient, etc., for a human adult (50 kg), a daily dose of 0.3 to 50 g of D-psicose, preferably 0.5 to 30 g, 1 to 20 g, or 3 to 15 g is appropriate. The duration of administration is not particularly limited, but it is preferable to take it continuously rather than as a single dose, preferably for a period of 1 day to 6 months, more preferably 3 days to 3 months, or 1 week to 5 weeks.

[0014] The compositions of the present invention can also be prepared by combining them with other anti-fatigue or fatigue recovery materials besides D-psicose. For example, the aforementioned imidazole dipeptides, whey protein hydrolysates, glutathione, vitamin B compounds, etc., can also be used in combination. [Examples]

[0015] The present invention will be described in detail and specifically below with reference to experimental examples, but the present invention is not limited to these experimental examples.

[0016] (raising mice) Thirteen 6-week-old C57BL / 6J mice were obtained and allowed to acclimate to their environment for one week. From the second week onward (7 weeks old and up), they were raised in an environment where they could freely run on a rotating wheel in their cage (ENV-047, Med Associates Inc, St Albans, VT, USA) (spontaneous exercise), and their daily exercise levels were measured (wheel management software was a USB interface (HUB) DIG-807, and the recording software was SOF-860). In addition, to acclimate them to forced exercise, they were given 30-minute treadmill runs (MK-690S, Muromachi Kikai Co., Ltd., Tokyo, Japan) twice a week (10m / min in the second week, 20m / min in the third week). From the fifth week onward (10 weeks of age and above), the mice were divided into two groups. One group was given a diet containing 3% D-psicose added to their regular diet, AIN93G powder (Oriental Yeast Co. Ltd., Tokyo, Japan) (administered group AE), while the other group was given a diet with 3% cellulose added to maintain a similar calorie content. Both groups were reared for four weeks (control group E).

[0017] (Fatigue recovery test (confirmation of constant exercise level)) The resilience from fatigue was determined by subjecting mice to forced exercise until they reached a state of complete fatigue, and then measuring the number of rotations of the rotating wheel in their cage per day. Prior to this fatigue recovery test, the daily exercise volume of the mice was confirmed. First, 9-week-old mice (average body weight 25.2 ± 0.13 g) before being fed D-psicose were made to run on a treadmill at a speed of 5 m / min for 10 minutes, and then the speed was increased to 20 m / min in increments of 2 m / min. The test was ended when the mice could no longer continue running even when their backs were pushed 5 times per minute (complete fatigue state). Immediately afterwards, the mice were transferred into the cage and the running volume (number of rotations) on the rotating wheel was measured daily. The results are shown in Figure 1. Figure 1 shows the average number of rotations of the rotating wheel in the cage by each 9-week-old mouse subjected to forced exercise, which was calculated daily, and this value was divided by the average number of rotations in the 7 days before forced exercise and plotted against the number of days elapsed. At this point, both the administration group AE and the control group E had not been administered D-psicose, and the grouping was retrospective. From these results, it was confirmed that there were not significant individual differences in the innate exercise ability of each mouse.

[0018] (Fatigue Recovery Test (Confirmation of Exercise Volume after Forced Exercise)) After the completion of the previous test to confirm the amount of constant exercise, the seven mice in the treatment group were switched to a diet supplemented with 3% D-psicose and raised for four weeks (during which time they were given exercise on a rotating wheel in their cages). The 13 mice, now 14 weeks old, were given a second forced exercise session. Immediately afterward, the mice were moved back into their cages, and the amount of running (number of rotations) on the rotating wheel was measured daily. The results are shown in Figure 2. Figure 2 plots the average number of rotations on the rotating wheel in the cage for each 14-week-old mouse that underwent the second forced exercise session, divided by the average number of rotations over the seven days prior to the second forced exercise session, against the number of days elapsed. As a result, immediately after forced exercise, the D-psicose administered group (AE group, mean body weight 26.4±0.13g, mean food intake 4.07±0.19g) exhibited greater activity levels than the control group (E group, mean body weight 27.0±0.13g, mean food intake 4.15±0.22g), and this trend continued until day 4. Furthermore, while the control group (E group, non-administered group) required more than 6 days to recover to normal activity levels, the D-psicose administered group (AE group) had already recovered to normal activity levels within 3 days after forced exercise.

[0019] From the above, it was found that administration of D-psicose improves the ability to recover from fatigue immediately after strenuous exercise and shortens the time required for recovery. Compositions containing D-psicose that have such effects can be used as anti-fatigue or fatigue recovery compositions.

Claims

1. A composition containing D-psicose for anti-fatigue or fatigue recovery.

2. The composition according to claim 1, wherein 0.3 to 50 g / kg body weight of D-psicose is ingested per day for 7 days or more.

Images